• Overview
  • Eligibility
  • More info
  • Locations

Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast (NCT00003857)

National Cancer Institute (NCI)
NRG Oncology
NCIC Clinical Trials Group
Cancer and Leukemia Group B
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. It is not yet known if radiation therapy is more effective than observation, with or without tamoxifen, in treating ductal carcinoma in situ. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with that of observation, with or without tamoxifen, in treating women who have ductal carcinoma in situ.
  • Drug: tamoxifen citrate
    • Procedure: adjuvant therapy
      • Radiation: radiation therapy
        Ages eligible for Study
        26 Years to 120 Years
        Genders eligible for Study
        Accepts Healthy Volunteers

        - Compare the efficacy of whole breast radiotherapy vs observation with or without optional tamoxifen in decreasing or delaying the appearance of local failure (both invasive and in situ) and preventing the need for mastectomy in women with good-risk ductal carcinoma in situ (DCIS) of the breast.

        - Compare distant disease-free survival of patients treated with these regimens.

        OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (under 50 vs 50 and over), final path margins (negative vs 3-9 mm vs at least 10 mm), mammographic size of primary (no greater than 1 cm vs greater than 1 cm to 2.5 cm), nuclei grade (low vs intermediate), and tamoxifen use (yes vs no). Patients are randomized to 1 of 2 treatment arms.

        - Arm I: Patients undergo observation and may receive optional oral tamoxifen once daily (at the discretion of the physician) for 5 years.

        - Arm II: Beginning within 12 weeks after final surgery, patients receive radiotherapy to the whole breast once daily, 5 days a week, for 3.5-5.5 weeks. Patients may receive optional tamoxifen as in arm I.

        Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.

        PROJECTED ACCRUAL: A total of 1,790 patients will be accrued for this study within 6 years.

        369 locations

        active not recruiting
        30 November, 1999
        17 May, 2017
        A girl giving information about available additional trials.

        FindMeCure helps you find, understand and join clinical trials from all over the world.

        There are more clinical trials for your condition!